Catalyst
Slingshot members are tracking this event:
Immunomedics (IMMU) Expects to Complete Phase 3 Trial Design for IMMU-130 in Metastatic Colorectal Cancer in early 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 21, 2016
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT01605318?term=immu-130&rank=1
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Trial Design, 2016, Immu-130
